Psoriasis is a chronic autoimmune systemic disease with an approximate incidence of 2%\nworldwide; it is commonly characterized by squamous lesions on the skin that present the typical\npain, stinging, and bleeding associated with an inflammatory response. In this work, poly(methyl\nvinyl ether-alt-maleic ethyl monoester) (PMVEMA-ES) nanofibers have been designed as a delivery\nvehicle for three therapeutic agents with palliative properties for the symptoms of this disease\n(salicylic acid, methyl salicylate, and capsaicin). For such a task, the production of these nanofibers\nby means of the electrospinning technique has been optimized. Their morphology and size have\nbeen characterized by optical microscopy and scanning electron microscopy (SEM). By selecting the\noptimal conditions to achieve the smallest and most uniform nanofibers, approximate diameters of\nup to 800â??900 nm were obtained. It was also determined that the therapeutic agents that were used\nwere encapsulated with high efficiency. The analysis of their stability over time by GC-MS showed\nno significant losses of the encapsulated compounds 15 days after their preparation, except in the\ncase of methyl salicylate. Likewise, it was demonstrated that the therapeutic compounds that were\nencapsulated conserved, and even improved, their capacity to activate the transient receptor potential\ncation channel 1 (TRPV1) channel, which has been associated with the formation of psoriatic lesions.
Loading....